医学
危险系数
2型糖尿病
内科学
前瞻性队列研究
优势比
人口
中性粒细胞与淋巴细胞比率
糖尿病
生物标志物
全身炎症
队列研究
比例危险模型
队列
置信区间
炎症
淋巴细胞
内分泌学
环境卫生
化学
生物化学
作者
Xiaoyan Guo,Shu Zhang,Qing Zhang,Li Liu,Hongmei Wu,Huanmin Du,Hongbin Shi,Chongjin Wang,Yang Xia,Xing Liu,Chunlei Li,Shaomei Sun,Xing Wang,Ming Zhou,Guowei Huang,Qiyu Jia,Honglin Zhao,Kun Song,Kaijun Niu
摘要
Aim It is widely known that inflammation is related to type 2 diabetes (T2D), but few studies have shown a direct relationship between the immune system and T2D using a reliable biomarker. Neutrophil:lymphocyte ratio (NLR) is an easy-to-analyze inflammation biomarker, but few studies have assessed the relationship between NLR and T2D. In order to evaluate how NLR is related to T2D, we designed a large-scale cross-sectional and prospective cohort study in an adult population. Subjects and methods Participants were recruited from the Tianjin Medical University General Hospital-Health Management Centre. Both a baseline cross-sectional ( n =87 686) and a prospective ( n =38 074) assessment were performed. Participants without a history of T2D were followed up for ∼6 years (with a median follow-up of 2.7 years). Adjusted logistic and Cox proportional hazards regression models were used to assess relationships between the quintiles of NLR and T2D (covariates: age, sex, BMI, smoking status, drinking status, hypertension, hyperlipidemia, and family history of cardiovascular disease, hypertension, hyperlipidemia, or diabetes). Results The prevalence and incidence of T2D were 4.9% and 6.8/1000 person-years respectively. The adjusted odds ratio and hazard ratio (95% CI) of the highest NLR quintile were 1.34 (1.21, 1.49) and 1.39 (1.09, 1.78) (both P for trend <0.01) respectively as compared to the lowest quintile of NLR. Leukocyte, neutrophil, and lymphocyte counts do not significantly predict the eventual development of T2D. Conclusion The present study demonstrates that NLR is related to the prevalence and incidence of T2D, and it suggests that NLR may be an efficient and accurate prognostic biomarker for T2D.
科研通智能强力驱动
Strongly Powered by AbleSci AI